Merianos, DJ, Tiblad, E, Santore, MT, Todorow, CA, Laje, P, Endo, M et al.. Maternal alloantibodies induce a postnatal immune response that limits engraftment following in utero hematopoietic cell transplantation in mice. J Clin Invest 119: 2590-2600

Children's Center for Fetal Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
The Journal of clinical investigation (Impact Factor: 13.22). 09/2009; 119(9):2590-600. DOI: 10.1172/JCI38979
Source: PubMed

ABSTRACT The lack of fetal immune responses to foreign antigens, i.e., fetal immunologic tolerance, is the most compelling rationale for prenatal stem cell and gene therapy. However, the frequency of engraftment following in utero hematopoietic cell transplantation (IUHCT) in the murine model is reduced in allogeneic, compared with congenic, recipients. This observation supports the existence of an immune barrier to fetal transplantation and challenges the classic assumptions of fetal tolerance. Here, we present evidence that supports the presence of an adaptive immune response in murine recipients of IUHCT that failed to maintain engraftment. However, when IUHCT recipients were fostered by surrogate mothers, they all maintained long-term chimerism. Furthermore, we have demonstrated that the cells responsible for rejection of the graft were recipient in origin. Our observations suggest a mechanism by which IUHCT-dependent sensitization of the maternal immune system and the subsequent transmission of maternal alloantibodies to pups through breast milk induces a postnatal adaptive immune response in the recipient, which, in turn, results in the ablation of engraftment after IUHCT. Finally, we showed that non-fostered pups that maintained their chimerism had higher levels of Tregs as well as a more suppressive Treg phenotype than their non-chimeric, non-fostered siblings. This study resolves the apparent contradiction of induction of an adaptive immune response in the pre-immune fetus and confirms the potential of actively acquired tolerance to facilitate prenatal therapeutic applications.

Download full-text


Available from: Philip Zoltick, May 15, 2014
43 Reads
  • Source
    • "November 2014 | Volume 7 | Article 89 | 3 younger and, therefore, smaller patients may well overcome any issue of production and also pre-existing antibodies against AAV9 (although an exclusion criteria in the SMA trial is the presence of anti-AAV9 antibodies at a titre of >1:50 as determined by ELISA binding immunoassay). However, high levels of maternal alloantibodies against AAV could trigger an immunization response through maternal microchimerism that is thought to play a role in the development of the fetal immune system (Merianos et al., 2009; Jeanty et al., 2014). A criticism of perinatal gene therapy is diagnosing a fetus or neonate early enough for therapeutic intervention. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurodegenerative monogenic diseases often affect tissues and organs beyond the nervous system. An effective treatment would require a systemic approach. The intravenous administration of novel therapies is ideal but is hampered by the inability of such drugs to cross the blood-brain barrier (BBB) and precludes efficacy in the central nervous system. A number of these early lethal intractable diseases also present devastating irreversible pathology at birth or soon after. Therefore, any therapy would ideally be administered during the perinatal period to prevent, stop, or ameliorate disease progression. The concept of perinatal gene therapy has moved a step further toward being a feasible approach to treating such disorders. This has primarily been driven by the recent discoveries that particular serotypes of adeno-associated virus (AAV) gene delivery vectors have the ability to cross the BBB following intravenous administration. Furthermore, safety has been demonstrated after perinatal administration mice and non-human primates. This review focuses on the progress made in using AAV to achieve systemic transduction and what this means for developing perinatal gene therapy for early lethal neurodegenerative diseases.
    Frontiers in Molecular Neuroscience 11/2014; 7:89. DOI:10.3389/fnmol.2014.00089 · 4.08 Impact Factor
  • Source
    • "Growth retardation and developmental defects have been well documented in the progeny of irradiated mothers (8-11). In clinical radiotherapy, concern for radiation dose to the developing human fetus, in cases where maternal radiotherapy is indicated, include the critical need to calculate internal scatter dose as well as direct irradiation dose (12-14). Concern for irradiation teratogenic effects often enter discussions of termination of pregnancy if at early gestation, or delay in the initiation of radiotherapy to facilitate increased fetal growth, and early pre-term delivery (1, 2, 4). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the effects of Manganese superoxide dismutase (MnSOD) plasmid liposome (PL) maternal radioprotection on fetal mice, timed pregnant female mice (E14 gestation) were irradiated to 3.0 Gy total body irradiation (TBI) dose, and the number, weight, and growth and development over 6 months after birth of newborn mice was quantitated compared to irradiated controls. Maternal MnSOD-PL treatment at E13 improved pup survival at birth (5.4 ± 0.9/litter compared to irradiated 3.0 Gy controls 4.9 ± 1.1. There was no statistically significant difference in newborn abnormalities, male to female ratio in newborn litters, or other evidence of teratogenesis in surviving newborn mice from MnSOD-PL treated compared to irradiated controls. However, E13 3Gy irradiated pups from gene therapy treated mothers showed a significant increase in both growth and overall survival over 6 months after birth (p = 0.0022). To determine if transgene product crossed the placenta pregnant E13 mice were injected I.V. with hemagglutinin-epitope-tagged MnSOD (100 μgm plasmid in 100 μl liposomes), then 24 hours later fetal mice, placentas, and maternal tissues were removed and tested by both immunohistochemistry and RTPCR for transgene and product. There was no evidence of transgene or product in placenta or any fetal tissue while maternal liver was positive by both assays. The data provide evidence for fetal radioprotection by maternal MnSOD-PL gene therapy before irradiation which is mediated by an indirect bystander effect and is associated with a significant improvement in both survival at birth and growth and development of newborn mice.
    Gene therapy 01/2011; 18(6):579-83. DOI:10.1038/gt.2010.178 · 3.10 Impact Factor
  • Transplantation 08/2010; 90(4):462-3. DOI:10.1097/TP.0b013e3181eac3c1 · 3.83 Impact Factor
Show more